Evaluation Pipeline:
Prior to in-licensing projects, ValiRx conducts a rigorous scientific and commercial evaluation on the project. This 6-12 month period provides ValiRx with the right to assess whether the project is a good fit for the ValiRx pipeline. If the Evaluation is a success, a full license will be executed to license the project into a dedicated ValiRx subsidiary.
The scientific assessment typically consists of a range of cell based assays to understand and demonstrate the mechanism of action of the lead drug candidate; and to assess the disease area of highest potential.
The projects currently under evaluation are detailed below.
|
Project |
Originator |
Disease |
Molecule |
Date Evaluation Agreement Started |
|---|---|---|---|---|
|
|
||||
|
2021.2 |
Hokkaido University (Japan) |
Endometrial, Pancreatic, Bile duct Cancers |
Peptide |
16 December 2021 |
| 2022.1 | University of Barcelona (Spain) | Uterine and Pancreatic Cancers | Peptidomimetic KRAS binder |
10 February 2022 |
Once the Evaluation is complete a negotiation period is entered to set up the subsidiary and executed the license, after which the project is promoted to our in-house pipeline.